anabios

About anabios

This author has not yet filled in any details.
So far anabios has created 9 blog entries.

A Human Ex-Vivo Contractility-Based Assay for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-Arrhythmia Risk.

By | 2017-03-16T18:46:42+00:00 March 16th, 2017|

Thursday, March 16th from 8:30 am to 11:45 am: "A Human Ex-Vivo Contractility-Based Assay for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-Arrhythmia Risk." Hall A of the Exhibit Hall (Dr. Najah Abi-Gerges). If you will be at the meeting in March, please contact Alisen James: ajames@anabios.com, to let us know. We forward to connecting with both colleagues and [...]

​​​​AnaBios to attend the 2017 Society of Toxicology Annual Meeting and Exposition in Baltimore, MD, U.S.A.

By | 2017-02-13T18:41:38+00:00 February 13th, 2017|

Upcoming in March, AnaBios will be presenting and exhibiting at the 2017 Society of Toxicology Annual Meeting and Expo, taking place at the Baltimore Convention Center, March 13th – 16th. AnaBios’ exhibit/booth number is #519.  Dr.’s Paul Miller and Najah Abi-Gerges will be in attendance to discuss the latest in research and service offerings. Poster presentations [...]

AnaBios invited to speak at prestigious Gordon Research Conference in Ventura, CA

By | 2017-02-06T18:49:03+00:00 February 6th, 2017|

AnaBios invited to speak at prestigious Gordon Research Conference in Ventura, CA, February 6th – 10th, 2017. ​​Dr. Najah Abi-Gerges, Scientific Director for AnaBios, has been accepted to speak at The Gordon Research Conference in February 2017, in Ventura, CA. Dr. Abi-Gerges will speak on " “Proarrhythmia Predictions Using Primary Human Cardiomyocytes."   The Gordon [...]

Program will Accelerate Purdue’s Nav1.7 Sodium Ion Channel Drug Candidates with AnaBios’ Phase-X® Discovery Platform

By | 2016-12-05T18:50:30+00:00 December 5th, 2016|

December 5, 2016: Program will Accelerate Purdue’s Nav1.7 Sodium Ion Channel Drug Candidates with AnaBios’ Phase-X® Discovery Platform Purdue Pharma L.P. and AnaBios Corporation announced today a collaboration to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain. The goal of the collaboration is to accelerate Purdue's Nav1.7 sodium ion channel drug [...]

Purdue Pharma CEO discusses the alliance with AnaBios at BIO-Europe 2016 in Stockholm, Sweden

By | 2016-04-04T18:51:41+00:00 April 4th, 2016|

April 4 - 6, 2016: Purdue Pharma CEO discusses the alliance with AnaBios at BIO-Europe 2016 in Stockholm, Sweden. Purdue Pharma CEO, Mark Timney, discusses the company's strategy and the alliance with AnaBios, in an interview with Pharma Intelligence's Mike Ward. An excerpt of the interview is available by clicking on the video.   Video: 2016 Purdue [...]

AnaBios presents at 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic

By | 2015-09-28T18:53:16+00:00 September 28th, 2015|

September 28 - October 1, 2015: AnaBios presents at 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic.   The findings of collaborative work between AnaBios, AbbVie, Novartis and Roche were presented at the 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic. The presentation summarizes the results obtained employing Phase-X® ex-vivo human-based [...]

Purdue Pharma and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment

By | 2015-09-22T18:54:41+00:00 September 22nd, 2015|

September 22, 2015: Purdue Pharma and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment Project aims to Advance Nav1.7 Sodium Ion Channel Drug Candidates with Phase-X® Discovery Platform Purdue Pharma L.P. and AnaBios Corporation announced today the intent to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion [...]